Arbutus Biopharma Corporation (ABUS)
NASDAQ · Healthcare
Arbutus Biopharma Corporation Operating Income 2011–2025
Arbutus Biopharma Corporation annual/quarterly operating income history and growth rate from 2011 to 2026. Operating income (EBIT) is profit from core business operations, excluding interest and income taxes. It reflects the efficiency of a company's core operations.
- Arbutus Biopharma Corporation operating income for the quarter ending March 31, 2026 was 168.9 M, a 757.26% decrease year-over-year.
- Arbutus Biopharma Corporation operating income for the twelve months ending March 31, 2026 was 136.0 M, a 262.06% decrease year-over-year.
- Arbutus Biopharma Corporation annual operating income for 2025 was -38.2 M, a 50.00% decrease from 2024.
- Arbutus Biopharma Corporation annual operating income for 2024 was -76.3 M, a 2.28% decrease from 2023.
- Arbutus Biopharma Corporation annual operating income for 2023 was -78.1 M, a 19.32% increase from 2022.
- Arbutus Biopharma Corporation annual operating income for 2022 was -65.5 M.
Operating Income
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
Arbutus Biopharma Corporation Operating Income — FAQ
Arbutus Biopharma Corporation (ABUS) operating income over the last 15 years — annual and quarterly figures with year-over-year growth and charts.
What is Arbutus Biopharma Corporation's operating income?
Arbutus Biopharma Corporation (ABUS) reported operating income of -$38M for fiscal 2025.
Where can I see ABUS's operating income history?
The chart and table above show Arbutus Biopharma Corporation's operating income by year and by quarter, including the growth rate.